Javascript must be enabled to continue!
Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans? How can we harmonize behavioral research in humans and nonhuman species?
View through CrossRef
Professor Harriet de Wit, a pioneering researcher in psychoactive drugs at the University of Chicago, shares her remarkable 45-year scientific journey in this illuminating Genomic Press Interview. As Director of the Human Behavioral Pharmacology Laboratory and recipient of prestigious honors including the 2019 European Behavioral Pharmacology Society Distinguished Investigator Award, Dr. de Wit has revolutionized our understanding of how drugs like MDMA and LSD affect human behavior and consciousness. Her groundbreaking research, continuously funded by the National Institutes of Health for over 42 years—an extraordinary achievement in scientific excellence—has revealed crucial insights into the therapeutic potential of psychedelics and their effects on social connection, empathy, and neural function. Most recently, her laboratory demonstrated that MDMA enhances feelings of social connectedness during interpersonal interactions, findings that have profound implications for PTSD treatment and psychotherapy. As the expert consulted by renowned authors like Michael Pollan to understand psychedelic neuroscience, Dr. de Wit bridges the critical gap between animal research and human studies, using pioneering methodologies to translate behavioral observations across species. Her innovative work on microdosing, place preference procedures, and drug-induced neural actions has established new paradigms in addiction science and psychiatric treatment. She served as Field Editor for Psychopharmacology and Deputy Editor for Alcoholism: Clinical and Experimental Research for many years. Throughout her career, Dr. de Wit mentored numerous post-doctoral fellows and graduate students. Her life's work has been defined by curiosity, patience, and scientific rigor, first acquired as a graduate student from her advisor, Jane Stewart, at Concordia University. From her roots in Canada, Dr. de Wit went on to become one of the world's foremost authorities on psychopharmacology.
Title: Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans? How can we harmonize behavioral research in humans and nonhuman species?
Description:
Professor Harriet de Wit, a pioneering researcher in psychoactive drugs at the University of Chicago, shares her remarkable 45-year scientific journey in this illuminating Genomic Press Interview.
As Director of the Human Behavioral Pharmacology Laboratory and recipient of prestigious honors including the 2019 European Behavioral Pharmacology Society Distinguished Investigator Award, Dr.
de Wit has revolutionized our understanding of how drugs like MDMA and LSD affect human behavior and consciousness.
Her groundbreaking research, continuously funded by the National Institutes of Health for over 42 years—an extraordinary achievement in scientific excellence—has revealed crucial insights into the therapeutic potential of psychedelics and their effects on social connection, empathy, and neural function.
Most recently, her laboratory demonstrated that MDMA enhances feelings of social connectedness during interpersonal interactions, findings that have profound implications for PTSD treatment and psychotherapy.
As the expert consulted by renowned authors like Michael Pollan to understand psychedelic neuroscience, Dr.
de Wit bridges the critical gap between animal research and human studies, using pioneering methodologies to translate behavioral observations across species.
Her innovative work on microdosing, place preference procedures, and drug-induced neural actions has established new paradigms in addiction science and psychiatric treatment.
She served as Field Editor for Psychopharmacology and Deputy Editor for Alcoholism: Clinical and Experimental Research for many years.
Throughout her career, Dr.
de Wit mentored numerous post-doctoral fellows and graduate students.
Her life's work has been defined by curiosity, patience, and scientific rigor, first acquired as a graduate student from her advisor, Jane Stewart, at Concordia University.
From her roots in Canada, Dr.
de Wit went on to become one of the world's foremost authorities on psychopharmacology.
Related Results
Brain Organoids, the Path Forward?
Brain Organoids, the Path Forward?
Photo by Maxim Berg on Unsplash
INTRODUCTION
The brain is one of the most foundational parts of being human, and we are still learning about what makes humans unique. Advancements ...
Scientific substantiation of the principles of pharmaceutical correction of polydrug abuse based on forensic pharmacy
Scientific substantiation of the principles of pharmaceutical correction of polydrug abuse based on forensic pharmacy
The dissertation is devoted to the scientific substantiation of organizational and legal, forensic and legal principles of pharmaceutical correction of polydrug abuse as a result o...
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED]➢Item Name - Gro-X Brain➢ Creation - Natural Organic Compound➢ Incidental Effects - NA➢ Accessibility - Online➢ Rating - ⭐⭐⭐⭐⭐➢ Click Here To Visit - Official Website - ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
Prevalence of, Factors Associated with and Level of Dependence of Psychoactive Substance Use among Mekelle University Students, Ethiopia
Prevalence of, Factors Associated with and Level of Dependence of Psychoactive Substance Use among Mekelle University Students, Ethiopia
Background: Psychoactive substance use is a major public health concern globally. Though youth attending higher education institutions are considered particularly vulnerable to psy...
P03-69 The introduction of psychoactive drugs in portugal in the 1950's
P03-69 The introduction of psychoactive drugs in portugal in the 1950's
The authors present some results of an ongoing research on the introduction of psychoactive drugs in Portugal during the 1950's.This study analyses medical papers published in the ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...

